RRM2 and renal carcinoma: In conclusion, our results suggest that RRM2 overexpression in renal cancer cells plays a key role in sunitinib resistance in patients with RCC and that RRM2 competes with UBE3A to bind to the C‐terminus of ANXA1, preventing ANXA1 degradation.